Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hospital data reveals clues about pneumonia relapses

NCT ID NCT06517277

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study reviewed medical records of 203 adults hospitalized with Haemophilus influenzae pneumonia across 13 hospitals. Researchers aimed to find factors linked to early relapse (within 90 days) and severe outcomes like intensive care or death. By analyzing patient data, they hope to improve care for those at higher risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which patients are at higher risk of relapse or severe pneumonia, leading to better monitoring and treatment strategies.
What could go wrong
This is a retrospective observational study, so it can only show associations, not cause and effect. Results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

203 people

The number who actually took part.

Started

Jul 2024

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hospitalized patients for a Haemophilus influenzae pneumonia in 14 hospitals of Assistance Publique - Hôpitaux de Paris, between 09/01/2022 to 08/31/2023.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Acute respiratory symptoms: cough and/or dyspnea and/or purulent sputum or worsening of the color of the sputum for patients with chronic respiratory pathology, chest pain, desaturation defined by saturation \< 95% in ambient air * Inflammatory syndrome: fever ≥ 38.5°C or CRP ≥ 30 mg/L * Pulmonary imaging (x-ray or CT scan) compatible with pneumonia * Good quality respiratory sample (for cytobacteriological examination of sputum (CBES) : leukocytes \> 25/mm3 and cells \< 10/mm3) positive in culture for H. influenzae at a significant threshold (for CBES ≥ 107 CFU/mL, for "standard" bronchial aspirate ≥ 105 CFU/mL, for protected bronchial aspiration ≥ 103 CFU/mL, for bronchoalveolar lavage ≥ 104 CFU/mL) * Respiratory antibiotic therapy started by the clinician Exclusion Criteria: * Age \< 18 years * Opposition formulated (following receipt of the study information note) * Legal protection measure (impossibility of collecting non-opposition) * Ventilator-associated pneumonia (VAP)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Haemophilus influenzae pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

haemophilus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Haemophilus influenzae pneumonia

Contacts and locations

Locations

  • Hôpital Beaujon

    Clichy, 92110, France

  • Hôpital Bichat

    Paris, 75018, France

  • Hôpital Béclère

    Clamart, 92140, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Européen Georges Pompidou

    Paris, 75015, France

  • Hôpital La Pitié Salpêtrière

    Paris, 75013, France

  • Hôpital Lariboisière

    Paris, 75010, France

  • Hôpital Necker-Enfants Malades

    Paris, 75015, France

  • Hôpital Raymond Poincaré

    Garches, 92380, France

  • Hôpital Saint-Antoine

    Paris, 75012, France

  • Hôpital Saint-Louis

    Paris, 75010, France

  • Hôpital du Kremlin-Bicêtre

    Le Kremlin-Bicêtre, 94270, France